Recap: G1 Therapeutics Q4 Earnings
Recap: G1 Therapeutics Q4 Earnings
Shares of G1 Therapeutics (NASDAQ:GTHX) rose in after-market trading after the company reported Q4 results.
的股份G1治疗公司(纳斯达克:GTHX)在盘后交易中上涨,此前该公司公布了第四季度业绩。
Quarterly Results
季度业绩
Earnings per share rose 28.72% year over year to ($0.67), which beat the estimate of ($0.87).
每股盈利较上年同期增长28.72%至0.67美元,超过预估的0.87美元。
Revenue of $16,546,000 up by 0.00% from the same period last year, which beat the estimate of $4,060,000.
营收为16,546,000美元,比去年同期增长0.00%,超过了预期的4,060,000美元。
Looking Ahead
展望未来
G1 Therapeutics hasn't issued any earnings guidance for the time being.
G1治疗公司暂时没有发布任何盈利指引。
Revenue guidance hasn't been issued by the company for now.
该公司目前尚未发布营收指引。
How To Listen To The Conference Call
如何收听电话会议
Date: Feb 24, 2021
日期:2021年2月24日
Time: 04:30 PM
时间:下午4时30分
ET Webcast URL: https://edge.media-server.com/mmc/p/n2his4rc
Price Action
价格行动
Company's 52-week high was at $37.07
该公司52周高点为37.07美元
Company's 52-week low was at $8.80
该公司52周低点为8.80美元
Price action over last quarter: Up 116.89%
上个季度的价格走势:上涨116.89%
Company Profile
公司简介
G1 Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat most types of cancer such as cell lung cancer and breast cancer and designs them to combine - and enhance - the anti-tumor activity of current therapies.
G1治疗公司是一家临床阶段的生物制药公司。它致力于开发新的小分子疗法,以针对癌症治疗中未得到满足的需求。该公司正在开发有潜力治疗大多数类型癌症的药物,如细胞肺癌和乳腺癌,并设计这些药物来结合-并增强-当前疗法的抗肿瘤活性。
译文内容由第三方软件翻译。